Keros Therapeutics, Inc. (KROS) Misses Q1 EPS by 14c

Keros Therapeutics, Inc. (NASDAQ: KROS) reported Q1 EPS of ($1.26), $0.14 worse than the analyst estimate of ($1.12).

For earnings history and earnings-related data on Keros Therapeutics, Inc. (KROS) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance
• Casey's General Stores (CASY) Tops Q1 EPS by 69c